Colitis ulcerosa – ein Update

Dieses Update zur Pathogenese, Diagnostik und Therapie der Colitis ulcerosa bringt die Komplexität der Krankheitsentstehung zwischen Mikrobiom und Barriere auf den neuesten Stand. Des Weiteren wird das neue diagnostische Vorgehen bei der Karzinomprävention erläutert und entsprechend der kürzlich überarbeiteten Leitlinie der DGVS auch der therapeutische Algorithmus aktualisiert.

Schlüsselwörter

Colitis ulcerosa - Immunsuppression - Biologika - ileoanaler Pouch

• Literatur

• 1 Stange EF. Hrsg. Entzündliche Darmerkrankungen. Klinik, Diagnostik und Therapie. Stuttgart: Schattauer; 2015
• 2 Cleynen I, Boucher G, Jostins L. Inherited determinants of Crohnʼs disease and ulcerative colitis phenotypes: a genetic association study. Lancet 2016; 387: 156-167
• 3 Franzosa EA, Morgan XC, Segata N. et al. Relating the metatranscriptome and metagenome of the human gut. Proc Natl Acad Sci U S A 2014; 111: E2329-E2338
• 4 Wehkamp J, Frick JS, Stange EF. Rolle des Mikrobioms und die gastrointestinale Barrierefunktion – klinische Implikationen. Gastroenterologie up2date 2016; 12: 289-301 doi:10.1055/s-0042-117562
• 5 Haberman Y, Karns R, Dexheimer PJ. et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun 2019; 10: 38 doi:10.1038/s41467-018-07841-3
• 6 Kucharzik T, Dignass A, Atreya R. et al. Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2018; 56: 1087-1169
• 7 Gasia MF, Ghosh S, Panaccione R. et al. Targeted biopsies identify larger proportions of patients with colonic neoplasia undergoing high-definition colonoscopy, dye chromoendoscopy, or electronic virtual chromoendoscopy. Clin Gastroenterol Hepatol 2016; 14: 704-712
• 8 Watanabe T, Ajioka Y, Mitsuyama K. et al. Comparison of targeted vs. random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology 2016; 151: 1122-1130
• 9 Marteau P, Probert CS, Lindgren S. et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo-controlled study. Gut 2005; 54: 960-965
• 10 Sandborn WJ, Travis S, Moro L. et al. Once-daily budesonide MMX^® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: 1218-1226
• 11 Lichtiger S, Present DH, Kornbluth A. et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845
• 12 Schmidt KJ, Müller N, Dignass A. et al. Long-term outcomes in steroid-refractory ulcerative colitis treated with tacrolimus alone or in combination with purine analogues. J Crohns Colitis 2016; 10: 31-37
• 13 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
• 14 Laharie D, Bourreille A, Branche J. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
• 15 Feagan BG, Rutgeerts P, Sands BE. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710
• 16 Sandborn WJ, Su C, Sands BE. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376: 1723-1736
• 17 Harbord M, Eliakim R, Bettenworth D. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis 2017; 11: 769-784 doi:10.1093/ecco-jcc/jjx009
• 18 Panaccione R, Ghosh S, Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400.e3
• 19 Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; (02) CD000544
• 20 Kruis W, Fric P, Pokrotnieks J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623
• 21 Narula N, Kassam Z, Yuan Y. et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis 2017; 23: 1702-1709
• 22 Fazio VW, Kiran RP, Remzi FH. et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg 2013; 257: 679-685
• 23 Harnoy Y, Desfourneaux V, Bouguen G. et al. Sexuality and fertility outcomes after hand sewn versus stapled ileal pouch anal anastomosis for ulcerative colitis. J Surg Res 2016; 200: 66-72
• 24 Lepistö A, Sarna S, Tiitinen A. et al. Female fertility and childbirth after ileal pouch-anal anastomosis for ulcerative colitis. Br J Surg 2007; 94: 478-482